Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when
combined with a standard regimen of gemcitabine in approximately 50 subjects with solid
tumors and measurable disease.